You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Medtronic
McKesson
Mallinckrodt
Boehringer Ingelheim

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DORNASE ALFA

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for dornase alfa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00204685 Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa Unknown status Joachim Riethmueller, Dr. med. Phase 2/Phase 3 2003-08-01 The purpose of this study is to determine whether Inhalation of Recombinant Human Deoxyribonuclease Shortens Ventilation Time in Mechanically Ventilated Adults
NCT00204685 Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa Unknown status University Hospital Tuebingen Phase 2/Phase 3 2003-08-01 The purpose of this study is to determine whether Inhalation of Recombinant Human Deoxyribonuclease Shortens Ventilation Time in Mechanically Ventilated Adults
NCT00265434 Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis Completed Dr. Gerlind Schneider Phase 3 2005-12-01 Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.
NCT00265434 Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis Completed PD Dr. Assen Koitschev, Tübingen Phase 3 2005-12-01 Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.
NCT00265434 Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis Completed PD Dr. Joachim Riethmöller, Tübingen Phase 3 2005-12-01 Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.
NCT00265434 Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis Completed University of Jena Phase 3 2005-12-01 Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of Chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of the efficacy of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for dornase alfa

Condition Name

Condition Name for dornase alfa
Intervention Trials
Cystic Fibrosis 5
Atelectasis 2
Ventilation, Mechanical 1
Chronic Rhinosinusitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for dornase alfa
Intervention Trials
Fibrosis 5
Cystic Fibrosis 5
Sinusitis 3
Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for dornase alfa

Trials by Country

Trials by Country for dornase alfa
Location Trials
United States 23
Germany 5
Australia 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for dornase alfa
Location Trials
Ohio 2
New Jersey 2
South Dakota 1
Tennessee 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for dornase alfa

Clinical Trial Phase

Clinical Trial Phase for dornase alfa
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 2/Phase 3 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for dornase alfa
Clinical Trial Phase Trials
Completed 8
Unknown status 3
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for dornase alfa

Sponsor Name

Sponsor Name for dornase alfa
Sponsor Trials
Genentech, Inc. 6
University of Jena 2
Hoffmann-La Roche 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for dornase alfa
Sponsor Trials
Other 18
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Harvard Business School
Colorcon
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.